Velscope Oral Cancer Screenings
Oral cancer is on the rise. Could you be at risk? Learn about the lifesaving screening tests that you need and the warning signs you can't miss....
One of the VELscope system's most important tasks is to help identify areas that might, if not identified and treated, progress to oral cancer. The statistics below, from the National Cancer Institute's SEER Database, 1999-2006, are a compelling argument for regular VELscope exams:
Found early, while still Localized (confined to the primary site), oral cancer's five-year survival rate is good: about 83%. Only 33% of all oral cancer discoveries fall into this category.
Found while Regional (progressed to regional lymph nodes) the five-year survival rate drops significantly, to about 55%. Approximately 46% of all oral cancer discoveries are Regional.
Found late, oral cancer's five-year survival rate is poor: approximately 32%. This accounts for approximately 14% of all oral cancer findings.
Finding oral cancer in its early stages is crucial. The VELscope offers hope for the early discovery of oral pre-cancers and cancers by providing Dr. Doctor and his hygienist with visual information that may not be apparent under ordinary light.
The VELscope system helps dental professionals visualize abnormalities in the mucosal tissues of your lips, mouth and upper larynx. In just two minutes, with no rinses, stains or discomfort, a VELscope examination lets healthcare professionals improve their assessment of your overall oral health.
The VELscope's blue light "excites" molecules (called "fluorophores") deep within the layers of oral mucosal tissues. In turn, those fluorophores emit their own light (fluorescence), in shades of green, yellow and red. The VELscope's proprietary filter makes fluorescence visualization possible, by blocking reflected blue light, and by enhancing the contrast between normal and abnormal tissue.
Please watch the following eight-minute video addressing a real-life situation involving the dangers of HPV, and relation to oral cancer.